[Edaily Reporter Kwon Oh-seok] #Vibozon, an affiliate of Vibozon Pharmaceuticals, announced on the 9th that it has been selected for two major projects simultaneously under the “2026 Bio-Health Global Expansion Support Program (K-VIP)” organized by the Korea Health Industry Development Institute (KHIDI).

This project is a national strategic program designed to promote the overseas expansion of domestic biohealth companies, with the aim of providing comprehensive support for responding to import/export regulations, expanding global partnerships, and strengthening technological competitiveness. Among these, Vivazon was selected for two projects: △ the Global Expansion Expert Consulting Support Project and △ the Growth Stage-Specific Technology Cooperation Acceleration Support Project.
The Global Expansion Expert Consulting Support Program is designed to strengthen the capabilities of pharmaceutical and biotech companies in establishing overseas strategies and addressing regulatory challenges. Through this program, Vivzon plans to refine its U.S. market entry strategy for “Anaprazu,” Korea’s 38th innovative new drug and a non-narcotic analgesic, and to systematically develop a roadmap for global regulatory approval and commercialization.
The “Support Program for Accelerating Technology Cooperation by Growth Stage” focuses on accelerating technology development and commercialization through collaboration with leading global companies. Vivzon intends to expand its global network centered on key pipeline candidates such as Anaprazu and “VVZ-2471,” and concentrate its efforts on enhancing competitiveness during the clinical and commercialization phases.
A Vivzon official stated, “Being selected for this program has laid the groundwork for us to further refine our global regulatory response and clinical strategies,” adding, “We will continue to strengthen our position as an innovative new drug development company by expanding cooperation with global pharmaceutical companies and accelerating our entry into overseas markets.”